CN101948540B - Preparation of novel anti-EGFR human source antibody MIL27 and application thereof - Google Patents
Preparation of novel anti-EGFR human source antibody MIL27 and application thereof Download PDFInfo
- Publication number
- CN101948540B CN101948540B CN 201010275321 CN201010275321A CN101948540B CN 101948540 B CN101948540 B CN 101948540B CN 201010275321 CN201010275321 CN 201010275321 CN 201010275321 A CN201010275321 A CN 201010275321A CN 101948540 B CN101948540 B CN 101948540B
- Authority
- CN
- China
- Prior art keywords
- antibody
- egfr
- mil27
- cell
- erbitux
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention discloses an anti-EGFR human source antibody MIL27 based on computer aided design and application thereof. The antibody can be used for obviously inhibiting and killing human cancer cell expressing EGFR. The invention is based on the interaction structure characteristic of EGFR protein extracellular region and functional antibody, computer virtual screening and design are adopted to obtain the anti-EGFR functional human source antibody MIL27, PCR method is applied to complete synthesis of antibody gene, eukaryotic expression vector is constructed, and MIL27 antibody capable of specifically identifying EGFR is expressed. The antibody MIL27 can effectively kill EGFR positive tumour cells, including blaster cancer cell and liver cancer cell. The antibody identifies EGFR new epitope, and competitive experiment verifies that the new epitope is different from EGFR epitope identified by Erbitux.
Description
Technical field
The present invention relates to new antibodies and uses thereof.Based on EGFR and functional antibodies interaction space structure, utilize epi-position constitutional features, the physico-chemical property of area of computer aided rational evaluation EGFR albumen and functional antibodies effect dynamic mode and functional antibodies specific recognition EGFR extracellular region functional domain, by the design of virtual screening and accessory molecule combine appropriate design, obtain new anti-EGFR human antibody MIL27.The applied molecular biology technology is carried out the complete synthesis and protein expression of gene, and by immunological experiment and Cell Biology Experiment the function of new antibodies is estimated.
Background technology
Human epidermal growth factor receptor (EGFR) gene is positioned at karyomit(e) p13～q22 district No. 7, and total length 200kb is made up of 28 exons, 1186 amino acid of encoding, the about 170kDa of EGFR strand glycoprotein molecule amount of formation.EGFR is one of the important molecule of cell signaling and cytodifferentiation [N.Prenzel, O.M.Fischer, S.Streit, S.Hart, A.Ullrich, The epidermal grouth factor receptor family as a central element for cellular signal transduction and diversification.Endocrine-related cancer8 (2001) 11-31].621 amino-acid residues of EGFR extracellular region (ECD) N-end are ligand binding domain, are made of I, II, four subprovinces of III, IV (or corresponding L1, S1/CR1, L2, S2/CR2 subprovince of being called).Leucine is rich in I and III district; Halfcystine is rich in II and IV district, and whole 50 cysteine residues participate in forming 25 intramolecular disulfide bonds.There is the glycosylation site that 12 potential N-glycosidic links connect in extracellular region in addition, and wherein I, II district respectively have 2, and III, IV district respectively have 4.Studies show that the glycosylation of EGFR is relevant with its participation binding partner and self homotype dimerization.EGFR strides film (TM) district by the hydrophobic region that 23 amino-acid residues constitute, and is strand α spiral.The EGFR intracellular region is totally 542 amino-acid residues, is made of membrane-proximal region (JM), Tyrosylprotein kinase (TK) district, three subprovinces of C-end region.Preceding 13 amino acid (645～657) of membrane-proximal region are that dimerization effect institute is essential in the mediation born of the same parents.The autophosphorylation site is positioned at the C-end, and wherein Tyr1068,1148,1173 is main site, and Tyr992,1086 is less important site, transmits closely related with signal.The overexpression of EGFR or abnormal activation usually cause malignant transformation of cells, thus with the generation of tumour, develop into pernicious and tumor operation prognosis etc. closely related.EGFR crosses in polytype human entity knurl and expresses, comprise [D.C.Moditahedi H such as lung cancer, colorectal carcinoma, mammary cancer, cancer of the stomach, the cancer of the brain, bladder cancer, tumor of head and neck, ovarian cancer, cancer of the stomach, prostate cancer and liver cancer, The receptor for EGF and its ligands:Expression, prognostic value and target for therapy in cancer.Int J Oncol (1994) 277-296].
The drug main of EGFR magnetic target therapy tumour will be divided into two classes at present: EGFR monoclonal antibody and micromolecular compound Tyrosylprotein kinase antagonist.The Tyrosylprotein kinase antagonist is mainly the small molecules quinolines, can competitive inhibition ATP and EGFR born of the same parents in the combination of tyrosine kinase domain, and then influence the tyrosine residues phosphorylation, the signal transduction in inhibition EGFR downstream.The EGFR monoclonal antibody is in conjunction with EGFR with the endogenic ligand competition, activation by suppressing Tyrosylprotein kinase, promote effect such as EGFR internalization to produce anti-tumour effect, comprise the cytotoxicity (antibody-dependent cell-mediated cytotoxicity, ADC C) of antibody dependent cellular mediation etc.Introduce 3 kinds of monoclonal antibody against EGFR that gone on the market below, compare with other chemotherapeutic, these antibody effect high specificities, side effect is little, has obtained curative effect preferably clinically.
Cetuximab (Erbitux) is the anti-EGFR people/mouse chimeric mAb of in February, 2004 FDA approval listing.Erbitux is made of the Fv district of mouse-anti EGFR antibody and people IGg1 heavy chain and κ constant region of light chain, and molecular weight is about 152kD.Erbitux and radiotherapy combined are used for the treatment of the early stage squamous cell carcinoma of the head and neck of regional area, share the treatment EGFR positive, transitivity colorectal cancer that the irinotecan chemotherapy is invalid with irinotecan.Erbitux is combined with tumor cell membrane surface EGFR specifically, the combination of part such as competitive inhibition EGF and TGF-α and EGFR.Though Erbitux in vivo anti-tumour effect mechanism and indeterminate, but analyzed in vitro and animal vivo test show, Erbitux be combined with EGFR the blocking-up phosphorylation and with the activation of receptor-associated kinase, thereby cell growth inhibiting, apoptosis-induced, reduce generation [the Ciardiello F of matrix metalloproteinase and VEGF121, TortoraG.A novel approach in the treatment of cancer:targeting the epidermal growthfactor receptor.Clin Cancer Res, 2001; 7:2958-2970].Erbitux can also make the EGFR internalization of surface of cell membrane, expression amount downward modulation [Kim ES, Khuri FR, Herbst RS, et al.Epidermal growth factor receptor biology.Cur Opin Oncol, 2001; 13:506-513]; Strengthen tumour cell to the susceptibility of chemotherapeutics such as irinotecan and radiotherapy, antitumous effect strengthens [Baselga J to some extent than independent chemotherapy or radiotherapy, Trigo JM, Bourhis J, et al.Phase IImulticenter study of the antiepidermal growth factor receptor monoclonalantibody cetuximab in combination with platinum based chemotherapy inpatients with platinum refractory metastatic and/or recurrent squamous cellcarcinoma of the head and neck.J Clin Oncol, 2005; 23:5568-5577].
Nimotuzomab (Tai Xinsheng) popular name obtains the SFDA approval in April, 2006 for reorganization human-derived anti-human EGF-R ELISA monoclonal antibody, is first human monoclonal antibody medicine of China, unites the III/IV nasopharyngeal carcinoma that is used for the treatment of the EGFR positive with radiotherapy.Nimotuzomab belongs to the IgG1 hypotype, molecular weight is 150kD, be by genetic engineering technique the complementary determining region of mouse monoclonal antibody (ioregf/r3) to be transplanted to monoclonal antibody against EGFR [the Crombet T that people's antibody skeleton constitutes, Osorio M, Cruz T, et al.Use of the humanized antiepidermal growth factorreceptor monoclonal antibody hr3 in combination with radiotherapy in thetreatment of locally advanced head and neck cancer patients.J Clin Onco l, 2004; 22:1646654].Nimotuzomab has the high-affinity (Kd=10 of being combined with EGFR
-9Mol/L), experiment in vivo and vitro proof nimotuzomab has inhibition of cell proliferation and blood vessel formation against function, and can promote natural death of cerebral cells, the retardance cell cycle rests on G1/S phase [CrombetRamos T, Rak J, Perez R, et al.Antiproliferative, antiangiogenic andproapoptotic activity of hR3:A humanized anti EGFR antibody.Int J Cancer, 2002; 101:567-575].Find during with its distribution in human body of the nimotuzomab of 99mTc marker research that nimotuzomab has at liver, the heart, kidney, bladder and spleen and accumulates, wherein liver accumulate the most remarkable.Except kidney, bladder and gi tract, each organ reduces along with the prolongation of time the intake of nimotuzomab, and this is because kidney, bladder and gi tract are Excretory organs of nimotuzomab.Tumour to the removing of nimotuzomab less than the removing of other healthy tissuess to nimotuzomab, and tumour to the intake of nimotuzomab with respect to more constant [the Crombet T of other organs, TorresL, Neninger E, et al.Pharmacological evaluation of humanized anti epidermalgrowth factor receptor, monoclonal antibody hr3, in patients with advancedepithelial derived cancer.J Immunother, 2003; 26:13948], the targeting of the tumour of this explanation nimotuzomab is strong, can reach high density at tumor locus and produce the effect that suppresses tumour.Security and the clinical efficacy of nimotuzomab estimated in I/II phase clinical study that nimotuzomab and chemotherapy combined are used.24 patients 16.7% have complete reaction, 20.8% stable disease.The mean value of all patients' survival time and median are respectively 16.76 and 14.77 months.What deserves to be mentioned is that the children of nimotuzomab and teenager's neurospongioma also have certain curative effect, and there is not a serious toxic side effect [Bode U, Buchen S, et al.Results of a phase II trial of hR3monoclonalantibody (nimotuzumab) in the treatment of resistant or relapsed high gradegliomas in children and adolescents.J Clin Oncol, 2006; 24 (18S): 1522].The general side effect of nimotuzomab is light moderate fever, ypotension, chatter, sore muscle and headache in I/II phase clinical study.Different with clinical other anti-egfr antibodies is that nimotuzomab has the little advantages of dermal toxicity probability such as the fash of generation, dermatitis.。
Panitumumab (VEXTIBIX) is a kind of complete humanized IgG 2 monoclonal antibody against EGFR of being produced by the XenoMouse technology, no mouse source property [Yang XD, Jia XC, Corvalan JR, et al.Development of ABX EGF, a fully human anti EGF receptor monoclonalantibody for cancer therapy.Crit Rev Oncol Hematol, 2001; 38:17-23].Panitumumab was gone on the market by the FDA approval in September, 2006, share or be used for the treatment of after chemotherapy the straight colorectal carcinoma of transitivity of the EGFR positive with fluorine pyrimidine, oxaliplatin and irinotecan.The same with other anti-egfr antibodies, the mechanism of action of panitumumab also is the combination by EGFR on blocking-up EGF and TGF-α and the tumour cell, the internalization of inducing EGFR, and then eliminate the cytological effect that EGFR mediates.In animal body in the test, compare with methods for the treatment of with other anti-egfr antibodies, tumor recurrence [Ciardiello F does not all appear in the animal major part after 8 months that only gives panitumumab, Caputo R, Bianco R, et al.Antitumor effect and potentiation of cytotoxic drugsactivity in human cancer cells by ZD 1839 (Iressa), an epidermal growth factorreceptor selective tyrosine kinase inhibitor.Clin Cancer Res, 2000; 6:2053-2063].No matter there are some researches show, be the tumour of high expression level or the low EGFR of expression, and panitumumab can both have its growth of inhibition.The normally modal untoward reaction of clinical application panitumumab of fash, relevant [the Foon KA with the dosage of panitumumab of the incidence of fash, Yang XD, Weiner LM, et al.Preclinical and clinical evaluations of ABX EGF, a fullyhuman anti epidermal growth factor receptor antibody.Int J Radiat Oncol B iolPhys, 2004; 58:984-990].Symptom such as also occur slight weakness, diarrhoea among the patient, feel sick, but and dosage indifference.Different with other EGFR target small-molecule drugs with the chimeric monoclonal antibody cetuximab of people mouse is even that at high dosage 2.5mg/ (kgwk), supersensitivity untoward reaction and the anti-people's antibody of people do not appear in the panitumumab in people source fully.
These three kinds of monoclonal antibody against EGFR of Cetuximab, panitumumab and nimotuzomab have all that targeting is strong, the relative features of smaller of toxic side effect.These monoclonal antibodies and chemicotherapy are combined in and are used for the treatment of the EGFR positive tumor clinically and have obtained certain curative effect.At present extensive not enough in the clinical application of China's monoclonal antibody against EGFR, expense is also higher relatively.Monoclonal antibody against EGFR fails separately to be used for tumor treatment, also needs and radiotherapy or chemotherapy combined are used; And clinical to be used for the treatment of tumor type also less, these have limited monoclonal antibody against EGFR use clinically to a certain extent.
The present invention is according to the structure and properties of present EGFR albumen and the research background of antibody thereof, utilize the special constitutional features of EGFR, EGFR extracellular region and functional antibodies Erbitux interaction space conformation and ad hoc structure characteristic of field, by computer virtual screening and molecular designing conceptual design novel anti-EGFR human antibody MIL27, and its function is verified and estimated by immunological experiment, Cell Biology Experiment and experimentation on animals.
Summary of the invention
The present invention is based on computer aided molecular design, and obtained novel anti-EGFR human antibody MIL27 by the molecular biology total synthesis method.
The novel human-derived antibody that anti-egfr antibodies MIL27 disclosed by the invention is based on EGFR structural domain, EGFR and functional antibodies interaction space conformation and physicochemical characteristics utilizes computer aided design (CAD) to obtain.
The invention discloses a kind of aminoacid sequence of novel anti-EGFR human antibody, it is characterized in that having as the described sequence of sequence table.The aminoacid sequence of the variable region of light chain of described EGFR humanized antibody MIL27 is selected from one of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5, and the aminoacid sequence of variable region of heavy chain is selected from and is one of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6.
A feature of antibody disclosed by the invention is that described antibody MIL27 identified epitope is different with Erbitux.Competition shows that in conjunction with experiment MIL27-1, MIL27-2 and MIL27-3 all do not compete combination with Erbitux, and they do not possess the same antigen epi-position.Wherein the aminoacid sequence of MIL27-1 variable region of light chain is SEQ ID NO:1, and the aminoacid sequence of variable region of heavy chain is SEQ ID NO:2; The aminoacid sequence of MIL27-2 variable region of light chain is SEQ ID NO:3, and the aminoacid sequence of variable region of heavy chain is SEQ ID NO:4; The aminoacid sequence of MIL27-3 variable region of light chain is SEQ ID NO:5, and the aminoacid sequence of variable region of heavy chain is SEQ ID NO:6.
The invention discloses EGFR human antibody MIL27 can be combined with target antigen positive cell surface EGFR specificity; The tumour cell that antibody MIL27 suppresses effectively and kills and wounds the EGFR positive is disclosed simultaneously.
Described antibody MIL27 can specificity mediate the ADCC function, kills and wounds SKVO3 and two kinds of target cells of HepG2 of the EGFR positive.
The invention also discloses the preparation method of novel anti-EGFR human antibody MIL27.
Specific implementation process is as follows:
1) the people source anti-egfr antibodies that utilizes computer aided molecular design to obtain;
2) utilize complete synthesis round pcr to synthesize the anti-egfr antibodies gene;
3) expression of antibody and evaluation;
4) the anti-egfr antibodies biologic activity is identified.
Describe design and the preparation process of anti-EGFR human antibody in detail below with reference to above-mentioned steps.Design and the method that prepare antibody of the present invention only are that methods involving is described, are not to be restrictive; Also can adopt other known methods, perhaps adopt the method for revising.
1) the people source anti-egfr antibodies that utilizes computer aided molecular design to obtain
Feature according to EGFR extracellular region structural domain functional epitope, utilize the small peptide (length is 10～15 amino acid) of computer virtual screening and computer aided molecular design method design antagonism EGFR function, and a series of function small peptides that will obtain are as the CDR district deposit of antibody variable region; The human antibody sequence information data storehouse that the antibody sequence that provides by Protein Data Banks such as being derived from TrEMBL, SwissProt, Kabat, IMGT makes up; By the homology mould build, the mechanics optimization technology carries out rational joint with human antibody variable region framework in the human antibody sequence information data storehouse and the CDR that lays in previously and makes up rational antibody variable region.
2) utilize complete synthesis round pcr to synthesize the anti-egfr antibodies gene;
According to the amino acid sequence of designerantibodies, be chosen in codon commonly used in the mammalian cell and carry out reverse translation, obtain corresponding antibody gene.Utilize the complete synthesis round pcr of gene, design corresponding primer, by the method acquisition full-length gene of overlapping PCR; Be cloned into cloning vector, carry out sequencing.
3) expression of antibody and evaluation
A) expression of antibody: antibody gene is built up in the carrier for expression of eukaryon, by liposome transfection, method transient transfection eukaryotic expression cell such as electricity commentariess on classics etc., gather in the crops supernatant after in the time of the cultivation sufficiently long, wherein contain the purpose antibody of expression.
B) double fastener heart enzyme-linked immunosorbent assay (ELISA): with behind the suitable antibody sandwich as capture antibody, after sealing, add testing sample and standard model and carry out capture reaction; Utilize suitable ELIAS secondary antibody to carry out color reaction subsequently, the content of target protein in the working sample.
C) SDS-PAGE: according to the polyacrylamide gel of the size of target protein preparation suitable concn, carry out polyacrylamide gel electrophoresis, protein isolate according to experiment needs preparation reduction electrophoresis sample or non-reduced electrophoresis sample; Through behind the coomassie brilliant blue staining, determine the target protein molecular weight.
4) the anti-egfr antibodies biologic activity is identified
A) flow cytometry: collect the purpose cell; After damping fluid (PBS+2% foetal calf serum) washing, add primary antibodie, 4 ℃ of reaction 30mins; Damping fluid washing 2 times adds corresponding two anti-ly, and 4 ℃ of lucifuges reaction 30mins are resuspended in after the damping fluid washing 2 times and directly carry out flow cytometry in the sheath fluid or fix with 1% Paraformaldehyde 96, and 4 ℃ keep in Dark Place.
B) antibody competition conjugated antigen experiment: behind the Erbitux antibody labeling isothiocyanate fluorescein (FITC), utilize the critical saturation concentration of flow cytometry technical measurement FITC-Erbitux identification target cell; With this critical saturation concentration and target cell reaction, the competition antibody that adds different concns simultaneously is at war with in conjunction with experiment, behind 4 ℃ of reaction 40mins, when Flow Cytometry analysis competition antibody existed, FITC-Erbitux was combined positive rate and fluorescence intensity with target cell.
C) cytotoxicity test (ADCC) of antibody dependence: mark EGFR positive cell is isolated peripheral blood mononuclear cell action effect cell as target cell with lymphocyte separation medium from peripheral blood; After the corresponding proportion mixing, add the antibody of inequality, on round bottom 96 well culture plates, carry out killing experiments, set up experimental port, the spontaneous release aperture of target cell, maximum release aperture and background hole; Hatch 2h for 37 ℃.Utilize multi-functional microplate reader to detect, calculate kill rate.
The people source anti-egfr antibodies that embodiment one, computer aided molecular design obtain
One, material:
InsightII 2005 routine packages (MSI molecular simulation, San Diego), this routine package comprises:
Hornology homology mould is built;
The Discover mechanics optimization;
Discover 3 normal temperature dynamics simulations;
The Docking molecular docking;
The apparent static potential energy of Delphi is analyzed.
Ludi molecular designing program (1995);
The IBM graphics workstation;
PDB 2008 databases (network www.rcsb.org download);
SwissProt database (2008, network download);
Kabat database (2001, network download);
IMGT database (2008, network download).
Two, methods and results:
Utilize the constitutional features of the EGFR extracellular region functional epitope of determining, can identify the short peptide sequence of this feature epi-position by the Ludi program through the design of fragment growth method; Utilize and from the beginning build the space conformation that is used in conjunction simulation antagonism small peptide with secondary structure prediction.
Human antibody variable region skeleton construction database by the antibody sequence information that is derived from network data base PDB, SwissProt, TrEMBL, Kabat, IMGT acquisition constitutes is spliced to form novel human-derived antibody variable region with above-mentioned antagonism small peptide reasonable combination.Utilize the antibody variable region sequence of design to build its space conformation through the homology mould technology of building.
Utilize the molecular docking method to make up antibody variable region and the interactional composite structure of antigen EGFR.Under the prerequisite of considering solvent effect, by the mixture model of normal temperature dynamics simulation acquisition antibody and AI, determine to act on the antibody variable plot structure of antigen EGFR by interaction energy.Further optimize the novel human-derived antibody variable region amino acid sequence that obtains, finally obtain heavy chain amino acid sequence (SEQ_ID NO:1, SEQ_ID NO:2, SEQ ID NO:3) and 3 light chain variable region amino acid sequences (SEQ_ID NO:4, SEQ_ID NO:5 and SEQ_ID NO:6) of 3 targeting EGFRs.
Expression and the evaluation of embodiment two, anti-EGFR human antibody MIL27
One, material:
Primer-design software is biosun software, and primer is synthetic by Shanghai Ying Jun Bioisystech Co., Ltd; Pyrobest DNA polymerase is TAKARA company product; DNTP is TAKARA company product; PGEM-T Easy vector system is Invitrogen company product; The T4DNA ligase enzyme is NEB company product; Gene sequencing is finished by Sinogenomax Co., Ltd.; Antibody carrier for expression of eukaryon pTGS-FRT-DHFR is made up by our company and the (license number: ZL200510064335.0) of application national patent; Liposome, MTT are Invitrogen company product, and goat anti-human igg, the goat anti-human igg who reaches the horseradish enzyme labelling and human IgG are our company's preparation; Restriction endonuclease is NEB company product; Other reagent are commercial product.
Two, methods and results
1.EGFR antibody gene is synthetic
Antibody gene sequence according to the computer simulation acquisition, gene order SEQ ID NO:7, the SEQ ID NO:8 and the SEQ ID NO:9 that comprise variable region of heavy chain, the gene order SEQID NO:10 of variable region of light chain, SEQ ID NO:11 and SEQ ID NO:12.Be chosen in the higher codon of frequency of utilization in the mammalian cell, with the antibody weight chain variable region aminoacid sequence reverse translation that the Computer Design screening obtains, obtain the variable region nucleotide sequence of antibody; The principle complete synthesis according to gene utilized computer aided design software, design primer, correlation parameters such as the secondary structure of consideration primer, GC content; Adopt the complete synthesis antibody weight of overlapping pcr variable region gene.
2. the expression of antibody
2.1 antibody Construction of eukaryotic
That selects that our company obtains contains human IgG1's antibody constant region expression carrier pTGS-FRT-DHFR (license number: ZL200510064335.0) as the expression vector of antibody of the present invention.3 antibody chain variable region genes of the described acquisition of present embodiment step 1,3 heavy chain variable region genes are carried out the random pair combination, be cloned in the pTGS-FRT-DHFR carrier.Through transforming equimolecular biology common technology, obtain the carrier for expression of eukaryon of 9 antibody altogether.
2.2 antibody expression
With the carrier for expression of eukaryon that obtains, to Chinese hamster ovary celI, gather in the crops supernatant by liposome-mediated method transient transfection behind the 48h, by the expression of experimental analysis purpose antibody such as double fastener heart ELISA method and SDS-PAGE.
Utilize the goat anti-human igg of goat anti-human igg and horseradish enzyme labelling to carry out the content that double fastener heart ELISA method detects antibody in the supernatant, as negative control, the pure product of human IgG are as standard substance with the untransfected supernatant.Experimental result shows, the antibody weight chain variable region gene random pair combination that computer aided design (CAD) obtains is expressed, and has target protein in the supernatant of results and expresses.Carry out the SDS-PAGE experiment with non-reducing form, the result shows that the target protein of expression is about 155KDa, meets the molecular weight (Fig. 1) of antibody; Goat anti-human igg with the horseradish enzyme labelling carries out Western Blotting detection, and expressing the target protein that obtains can be had human IgG antibody's feature (Fig. 2) by goat anti-human igg's specific recognition; But gene successful expression in eukaryotic cell that the antibody sequence that prompting obtains obtains through reverse translation, expressing the albumen that obtains is antibody molecule, has typical IgG antibody feature.
2.3 antibody is identified
Collect EGFR positive cells SKOV3, get lysate behind the M2 damping fluid lysing cell and carry out Western Blotting experiment, the antibody weight chain variable region gene random pair combination that computer aided design (CAD) is obtained is expressed 9 antibody obtaining as detecting antibody, detects with the goat anti-human igg of horseradish enzyme labelling.Experimental result shows, but the equal specific recognition target protein of each antibody, its molecular weight is about 185KDa (Fig. 3), prompting, and the antibody MIL27 of acquisition can specific recognition target antigen EGFR.
The functional trial of embodiment three, anti-egfr antibodies MIL27
EGFR human antibody MIL27-1, MIL27-2 and MIL27-3 are example, further verify the biological function of antibody.
One, material
Breast cancer cell line SKVO3 and hepatoma cell line HepG2 are available from ATCC; DELFIAEuTDA cytotoxicity test kit is PE company product; Other related reagents are referring to embodiment two.
Two, methods and results
1. the combination of flow cytometry MIL27 and cell surface EGFR
With the positive breast cancer cell line SKVO3 of EGFR, three kinds of cells of hepatoma cell line HepG2 and lung cancer cell line A549 detect the ability of the MIL27 antibodies cell surface EGFR antigen of different concns as target cell; With Erbitux antibody as positive control.The result shows MIL27 energy specific recognition target cell, and it is in conjunction with positive rate similar to control antibodies Erbitux (table 1, table 2, table 3), and the identification of prompting antibody MIL27 is active consistent with control antibodies Erbitux.
Table 1FACS detects the combination activity of MIL27-1 and cell surface EGFR
Table 2FACS detects the combination activity of MIL27-2 and cell surface EGFR
Table 3FACS detects the combination activity of MIL27-3 and cell surface EGFR
2. the competitiveness of antigen-antibody combination experiment
Behind Erbitux antibody labeling isothiocyanate fluorescein (FITC), utilize the critical saturation concentration of flow cytometry technical measurement FITC-Erbitux identification target cell SKOV3; The result shows that the FITC-Erbitux of 0.5 μ g/mL is combined with target cell SKOV3 and is critical state of saturation.With FITC-Erbitux and the target cell SKOV3 reaction of 0.5 μ g/mL, the competition antibody MIL27 that adds different concns simultaneously is at war with in conjunction with experiment, behind 4 ℃ of reaction 40mins, and Flow Cytometry analysis competition result; Fig. 4 result shows that antibody MIL27-1, MIL27-2, MIL27-3 can not compete FITC-Erbitux in conjunction with target cell; Even when the concentration of competition antibody when being 100 times of FITC-Erbitux antibody concentration (the competition antibody concentration is 50 μ g/mL), the combination of FITC-Erbitux and target cell change not yet; Prompting, though Erbitux and MIL27 identify EGFR, its epitope difference.
3. the cytotoxicity test (ADCC) that relies on of antibody
DELFIA EuTDA cytotoxicity test kit with PE company carries out the ADCC experiment, the positive breast cancer cell line SKVO3 of mark EGFR, hepatoma cell line HepG2 and lung cancer cell line A549 isolate peripheral blood mononuclear cell action effect cell as target cell with lymphocyte separation medium from peripheral blood; After the corresponding proportion mixing, add the antibody of inequality, on round bottom 96 well culture plates, carry out killing experiments, set up experimental port, the spontaneous release aperture of target cell, maximum release aperture and background hole; Hatch 2h for 37 ℃.Utilize multi-functional microplate reader to detect, calculate kill rate.The result shows that antibody MIL27 can effectively mediate the ADCC activity and kill and wound three kinds of cells, and its activity is antibody concentration and relies on; And under the same concentrations, MIL27 all is higher than Erbitux to the kill rate of three kinds of cells, prompting MIL27 mediation ADCC function kill and wound cell activity be significantly higher than Erbitux (Fig. 5, A: antibody-mediated ADCC effect is killed and wounded SKOV3 cell, B; Antibody-mediated ADCC effect is killed and wounded the HepG2 cell).
Description of drawings
Fig. 1 SDS-PAGE analyzes the MIL27 antibody that eukaryotic expression obtains.The antibody weight chain variable region gene that random pair combined computer aided design obtains carries out eukaryotic expression, and 9 antibody molecule amounts of acquisition are 155KDa; 9 antibody of 1～9 expression, M represents the molecular weight standard product.
Fig. 2 MIL27 antibodies specific is identified by the goat anti-human igg.9 antibody that the antibody weight chain variable region gene that random pair combined computer aided design obtains obtains all can be identified by the goat anti-human igg; 9 antibody of 1～9 expression; IgG represents that human IgG and Erbitux are together as positive control.
Fig. 3 MIL27 antibodies specific identification target antigen EGFR.Carry out Western Blottig with EGFR positive cell lysate and detect, 9 antibody that the antibody weight chain variable region gene that random pair combined computer aided design obtains obtains all can be identified the target antigen that molecular weight is 185KDa; 9 antibody of 1～9 expression, Erbitux is as positive control.
Fig. 4 MIL27 identification epitope is different with Erbitux.A:Erbitux antibody and target cell SKOV3 binding reactive; B:MIL27-1 does not compete in conjunction with target cell with Erbitux; C:MIL27-2 does not compete in conjunction with target cell with Erbitux; D:MIL27-3 does not compete in conjunction with target cell with Erbitux.
The external mediation of Fig. 5 MIL27 antibody ADCC effect is killed and wounded the EGFR positive cell.A: antibody-mediated ADCC effect is killed and wounded the SKOV3 cell, B: antibody-mediated ADCC effect is killed and wounded the HepG2 cell.
Claims (5)
1. anti-egfr antibodies, the aminoacid sequence of its variable region of light chain is selected from SEQ ID NO:1, and the aminoacid sequence of variable region of heavy chain is selected from SEQ ID NO:2.
2. the described antibody of claim 1 suppresses or kills and wounds purposes in the EGFR positive tumor cell medicine in preparation.
3. purposes as claimed in claim 2 is characterized in that, described EGFR positive tumor cell is breast cancer cell and liver cancer cell.
4. the described antibody of claim 1 is being made the purposes of respectively treating in the EGFR positive tumor medicine.
5. purposes as claimed in claim 4 is characterized in that, described EGFR positive tumor is mammary cancer and liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010275321 CN101948540B (en) | 2010-09-08 | 2010-09-08 | Preparation of novel anti-EGFR human source antibody MIL27 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010275321 CN101948540B (en) | 2010-09-08 | 2010-09-08 | Preparation of novel anti-EGFR human source antibody MIL27 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101948540A CN101948540A (en) | 2011-01-19 |
| CN101948540B true CN101948540B (en) | 2013-09-18 |
Family
ID=43452179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010275321 Expired - Fee Related CN101948540B (en) | 2010-09-08 | 2010-09-08 | Preparation of novel anti-EGFR human source antibody MIL27 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101948540B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102262155B (en) * | 2011-04-12 | 2013-10-09 | 百泰生物药业有限公司 | Method for measuring biological activity of recombined human epidermal growth factor and application of method |
| CN108250297B (en) * | 2018-01-23 | 2021-07-23 | 上海生物制品研究所有限责任公司 | anti-EGFR antibodies, methods of making and uses thereof |
| CN111875704B (en) * | 2020-06-23 | 2024-01-12 | 白先宏 | EGFR antibody and application thereof |
| CN112661844B (en) * | 2020-11-18 | 2022-05-03 | 贵州医科大学 | Single-chain antibody targeting EGFRvIII and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101602808A (en) * | 2008-06-12 | 2009-12-16 | 上海市肿瘤研究所 | Binding proteins specific and use thereof |
-
2010
- 2010-09-08 CN CN 201010275321 patent/CN101948540B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101602808A (en) * | 2008-06-12 | 2009-12-16 | 上海市肿瘤研究所 | Binding proteins specific and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| judith schmiedel et al..《matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization》.《cancer cell》.2009,第13卷(第4期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101948540A (en) | 2011-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geuijen et al. | Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade | |
| CN106977602B (en) | A kind of anti-PD1 monoclonal antibodies, its medical composition and its use | |
| CN105820251B (en) | Bispecific antibody or antibody mixture with common light chain | |
| CN107286242B (en) | The monoclonal antibody of anti-PD-1 | |
| WO2019068302A1 (en) | Antibodies specific to cd47 and pd-l1 | |
| CN110305212A (en) | Anti-cd 47 antibody and application thereof | |
| CN108136003A (en) | The use in conjunction of anti-PD-1 and anti-M-CSF antibody in treatment of cancer | |
| CN103772504B (en) | Humanization anti-epidermal growth factor receptor antibody and application thereof | |
| CN103003424A (en) | Antibody capable of binding to transforming growth factor alpha and having antiproliferative activity on cancer having Ras gene mutation | |
| CN101948540B (en) | Preparation of novel anti-EGFR human source antibody MIL27 and application thereof | |
| CN114621345A (en) | anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof | |
| CN109627340B (en) | CD3 and PRLR bispecific antibody and construction and application thereof | |
| Ohno et al. | Production and characterization of highly tumor‐specific rat monoclonal antibodies recognizing the extracellular domain of human L‐type amino‐acid transporter 1 | |
| CN110475788A (en) | Anti- CEACAM1 antibody and its application | |
| CN101633695B (en) | Preparation method of anti-erbB2 functional antibody based on erbB2 protein extracellular C-terminal functional epitope characteristics | |
| CN101875697B (en) | Design of novel anti-EGFR humanized antibody TGM10 and application thereof | |
| CN104530236B (en) | A kind of full people source HER2 antibody, its encoding gene and application | |
| CN109810194A (en) | The antibody and its preparation method and application of anti-DR5 | |
| Talavera et al. | Structure of the Fab fragment of the anti-murine EGFR antibody 7A7 and exploration of its receptor binding site | |
| TW201729832A (en) | Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38 | |
| CN102212135B (en) | Anti-vascular endothelial growth factor monoclonal antibody and application thereof | |
| CN110467676A (en) | Specifically bind the monoclonal antibody and its anticancer purpose of EGFR | |
| CN104650228A (en) | Full humanized HER2 antibody as well as coding gene and application thereof | |
| CN101817881B (en) | Light-chain variable region and heavy-chain variable region of FMU-EPCAM-4F6 monoclonal antibody | |
| CN103130896A (en) | Monoclonal antibody for resisting cell surface ectopic expression, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: Branch of Beijing economic and Technological Development Zone fourteen 100176 street Beijing City Hospital No. 20, No. 16 Building 5 unit 3 Co-patentee after: Institute of Basic Medical Sciences Patentee after: Beijing Mabworks Biotech Co., Ltd. Address before: 100176 Beijing City, Tongzhou District branch of Beijing economic and Technological Development Zone, fourteen Street No. 99 Building No. 3 Co-patentee before: Institute of Basic Medical Sciences Patentee before: Beijing Mabworks Biotech Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130918 Termination date: 20190908 |